U.S. Point of Care Technology Market Size, Share & Forecast 2026–2032

ID: MR-11872 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Point of Care Technology Market
  • ✓Market Size 2024: USD 17.8 billion
  • ✓Market Size 2032: USD 30.6 billion
  • ✓CAGR: 7.0%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Pharmacy channel reshaping demand: CVS Pharmacy and Walgreens run in-store CLIA-waived testing for influenza, strep, and COVID-19, shifting volume away from hospital core labs. Cartridge platforms from Abbott and QuidelOrtho capture this retail throughput, making consumables the fastest-growing profit pool in U.S. diagnostics.
FINDING 02
Reimbursement, not volume, constrains growth: The conventional view holds that test volume drives growth, yet Medicare Clinical Laboratory Fee Schedule rates, shaped by repeatedly delayed PAMA reforms, will determine which CLIA-waived assays survive. Low-complexity tests priced below device-plus-consumable costs face margin compression by 2027.
ANALYST RECOMMENDATION

Analyst Recommendation — File CLIA waivers early: Device makers should submit 510(k) applications bundled with CLIA waiver requests by the third quarter of 2026, targeting the 2027 Medicare Physician Fee Schedule cycle. Early waiver status places assays in pharmacy and physician office channels where reimbursement remains most durable.

U.S. Point-of-Care Technology: Market Overview

The U.S. point-of-care technology market is the largest national point-of-care testing market globally, estimated at USD 17.8 billion in 2024 and representing close to 40% of worldwide spending. Its distinctiveness comes from regulatory architecture: every test performed outside a central laboratory must clear FDA device review and carry a CLIA certificate, creating a two-gate entry sequence that few other countries impose. Hospitals, physician offices, urgent care centers, and retail pharmacies all compete for the same assays, and each setting carries different certification and reimbursement obligations.

Unlike the global norm, where emerging markets drive unit volume through low-cost glucose and infectious disease strips, U.S. demand skews toward higher-value molecular and immunoassay platforms. Abbott's ID NOW, Cepheid's GeneXpert systems, and Roche's cobas liat illustrate this premium positioning. Hospital emergency departments, primary care practices, and retail clinics account for the bulk of procedures, while home-use glucose monitoring remains the largest category by unit volume.

Growth Drivers in U.S. Point-of-Care Technology

Demographic pressure is the first driver. Adults aged 65 and older number roughly 61 million according to the U.S. Census Bureau, and this cohort generates disproportionate demand for diabetes, cardiac, and anticoagulation monitoring. Medicare reimbursement for remote physiologic monitoring, codified in CPT codes 99453 through 99458, has encouraged primary care practices to purchase bedside devices that feed electronic health records directly, and many practices have expanded device inventories since 2020.

Regulatory and funding shifts supply the second and third drivers. FDA's CLIA waiver pathway has produced dozens of waived tests in recent years, including influenza and COVID-19 antigen assays cleared under standard authorizations. The Rural Health Transformation Program, funded at USD 50 billion over fiscal years 2026 to 2030, directs states to equip underserved facilities with diagnostic equipment, creating a government-backed procurement channel for bedside platforms.

Market Restraints and Entry Barriers in U.S. Point-of-Care Technology

Reimbursement compression is the most immediate barrier. The Protecting Access to Medicare Act formula that governs Clinical Laboratory Fee Schedule rates has been delayed repeatedly, leaving CMS to adjust payment for waived tests on a rolling basis. New entrants must price against incumbents whose installed device bases generate recurring cartridge revenue, while Medicare payment for many low-complexity assays now falls below the combined cost of device and consumable.

Certification and integration form the second barrier. Each testing site requires a CLIA certificate from CMS, with a Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation determined by test complexity. New York adds a separate State Department of Health approval regime, and connecting devices to Epic and Oracle Health record systems requires HL7 interface validation that often extends hospital procurement cycles by six to twelve months.

Market Opportunities in U.S. Point-of-Care Technology

Pharmacy-based testing is the nearest large opening. CVS Pharmacy and Walgreens operate thousands of in-store testing points, and the addressable pharmacy pool for respiratory and sexually transmitted infection assays is estimated at USD 1.2 billion annually. Companies with CLIA-waived multiplex panels suited to pharmacist-administered protocols, particularly in states that authorize pharmacists to test and treat, can capture this channel within eighteen months of launch.

Sepsis and cardiac biomarker testing in emergency departments represents a second opening. The CDC estimates that 1.7 million American adults develop sepsis each year, and rapid pathogen identification at the bedside shortens time to appropriate antibiotics. Troponin and procalcitonin point-of-care assays addressing this gap represent an estimated USD 900 million addressable pool, with Texas and Florida emergency departments offering the highest patient throughput for early adoption.

Market at a Glance

MetricValue
Market Size 2024USD 17.8 billion
Market Size 2032USD 30.6 billion
Growth Rate (CAGR)7.0%
Most Critical Decision FactorDurability of Medicare Clinical Laboratory Fee Schedule reimbursement rates
Largest RegionSouth region, led by Texas, Florida, and Georgia
Competitive StructureConcentrated among diversified diagnostics majors, with fragmented niche device entrants

Leading Market Participants

  • Abbott
  • Danaher (Cepheid)
  • Roche Diagnostics
  • QuidelOrtho
  • Siemens Healthineers
  • bioMérieux
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific
  • Sysmex
  • Nova Biomedical

Regulatory and Policy Environment for U.S. Point-of-Care Technology

The FDA oversees device entry under the Federal Food, Drug, and Cosmetic Act, with in vitro diagnostic submissions filed through 510(k), De Novo, or PMA pathways and labeling governed by 21 CFR Part 809. CLIA waiver applications are reviewed within FDA's device center, while CMS administers the Clinical Laboratory Improvement Amendments of 1988 certificate system. The amended Quality Management System Regulation under 21 CFR Part 820 takes effect February 2, 2026, aligning device quality systems with ISO 13485 and adding audit requirements for manufacturers.

Reimbursement sits under the Medicare Clinical Laboratory Fee Schedule set by CMS, and PAMA reporting obligations continue to shape rates for waived and moderate-complexity tests. A federal court vacated FDA's laboratory-developed test rule in March 2025, preserving the existing oversight structure for hospital and reference laboratories. Section 524B of the FD&C Act requires premarket cybersecurity documentation for connected devices, adding roughly three to six months to submission timelines.

Long-Term Outlook for U.S. Point-of-Care Technology

By 2032 the U.S. market is projected to reach USD 30.6 billion, with molecular and multiplex platforms growing faster than glucose and coagulation categories. Pharmacy and home-adjacent settings will capture a larger share of respiratory and sexually transmitted infection volume, while hospital emergency departments remain the highest-value setting per test. Connected devices feeding Epic and Oracle Health records will become standard procurement criteria across most institutional buyers.

Consolidation will continue as diversified diagnostics firms acquire niche cartridge makers, and CLIA-waived molecular assays will become standard in physician offices. Reimbursement reform, particularly any replacement of the PAMA formula, would reset pricing across the entire channel and reward manufacturers with low-cost, high-throughput cartridges. Manufacturers that secure waivers and integrate with major EHR vendors will hold the strongest positions through the forecast period.

Frequently Asked Questions

Devices must obtain FDA clearance through 510(k), De Novo, or PMA review, followed by CLIA categorization and a waiver application. Commercial launch typically follows 12 to 18 months after the initial submission.
Pharmacies performing waived tests hold a Certificate of Waiver and must follow manufacturer instructions exactly. Moderate-complexity testing requires a Certificate of Compliance or Certificate of Accreditation.
Medicare pays under the Clinical Laboratory Fee Schedule for tests performed in qualifying settings. Rates remain subject to PAMA-driven adjustments that have been repeatedly delayed.
New York requires State Department of Health approval for every test sold or performed within the state. California and other states impose their own laboratory licensing requirements.
Texas and Florida combine high-volume outpatient demand with favorable pharmacist testing authority. Large Medicare Advantage enrollment in both states accelerates reimbursement-driven adoption.

Market Segmentation

By Product Type
  • Glucose Monitoring Systems
  • Infectious Disease Testing
  • Cardiac Markers
  • Coagulation Testing
  • Blood Gas and Electrolyte Analyzers
By End User
  • Hospitals and Emergency Departments
  • Physician Offices
  • Retail Pharmacies
  • Home Healthcare
  • Urgent Care Centers
By Technology
  • Molecular Diagnostics
  • Immunoassay
  • Biosensors
  • Lateral Flow Immunochromatography
  • Hematology

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Point-of-Care Technology - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Glucose Monitoring Systems
4.2 Infectious Disease Testing
4.3 Cardiac Markers
4.4 Coagulation Testing
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals and Emergency Departments
5.2 Physician Offices
5.3 Retail Pharmacies
5.4 Home Healthcare
5.5 Others
Chapter 06 Technology Insights
6.1 Molecular Diagnostics
6.2 Immunoassay
6.3 Biosensors
6.4 Lateral Flow Immunochromatography
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Abbott
7.2.2 Danaher (Cepheid)
7.2.3 Roche Diagnostics
7.2.4 QuidelOrtho
7.2.5 Siemens Healthineers
7.2.6 bioMérieux
7.2.7 Becton, Dickinson and Company
7.2.8 Thermo Fisher Scientific
7.2.9 Sysmex
7.2.10 Nova Biomedical
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.